At Ventijet we develop medical devices and solutions aimed at providing personalized therapy for patients under intensive care. Our activity focuses on supplying the necessary equipment for these therapies, which includes a ventilator with its own ventilation mode and a predictive system for monitoring respiratory parameters. Additionally, we have a strong medical team, highly involved in the development of our devices, providing input as end-users.
In recent decades, there have been no significant advances in the way conventional ventilators deliver breaths. At Ventijet, we developed an innovative ventilation mode that has shown excellent results during clinical trials, especially for patients suffering from Acute Respiratory Distress Syndrome (ARDS), achieving better oxygenation than conventional devices.
Our other development branch, AVA is an advanced respiratory parameter monitoring device. Its operation is based on esophageal pressure measuring (a parameter gaining more relevance in the field of respiratory mechanics each day), from which a series of parameters are calculated to help clinicians determine the patient’s condition more accurately than the information obtained from a ventilator alone. Currently, AVA can provide 27 real-time parameters, but it’s the physician who must analyze and evaluate the information obtained. We are developing an upcoming version that will integrate a prediction algorithm based on the highest level of physiological knowledge. This will enable the individualization of therapies and the evaluation of the effects of different treatments. The goal is to democratize this knowledge so that clinicians who are not experts in respiratory mechanics can treat their patients with the same chances of success as an expert.